导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.36% | 3770/4773 |
| 近一周 | -1.97% | 985/5462 |
| 近一月 | -0.60% | 799/5421 |
| 近一季 | 4.31% | 317/5209 |
| 近半年 | -7.97% | 3290/4920 |
| 近一年 | -14.06% | 3631/4366 |
| 近两年 | 9.97% | 2807/2954 |
| 近三年 | -7.38% | 2009/2253 |
| 成立以来 | 15.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.70% 3921/4961 |
-12.99% 4449/5312 |
- - |
- - |
| 2025 | 0.97% 3238/4813 |
0.47% 1839/3635 |
-3.54% 3449/4076 |
6.02% 3557/4524 |
-1.74% 3005/4813 |
| 2024 | 9.07% 1497/3463 |
5.51% 355/2808 |
-5.19% 1665/3014 |
16.54% 1426/3129 |
-6.44% 2657/3463 |
| 2023 | -15.00% 1631/2656 |
2.34% 1371/2280 |
-10.32% 2103/2385 |
-2.30% 659/2515 |
-5.21% 1291/2655 |
| 2022 | -16.17% 457/2207 |
-19.71% 1487/1919 |
17.75% 117/2016 |
-12.17% 661/2113 |
0.96% 1417/2208 |
| 2021 | -12.72% 1130/1822 |
-3.98% 840/1255 |
0.09% 1112/1330 |
-12.81% 1314/1466 |
4.16% 361/1822 |
| 2020 | 69.71% 73/1250 |
-9.77% 718/1028 |
28.36% 108/1067 |
17.84% 96/1164 |
24.35% 37/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证消费50ETF VS. 长安沪深300非周期A(740101) |